Douglas M. Hunt - 06 Jul 2026 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Reporting relationship: The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Issuer ticker: PBYI
Reported as of: 06 Jul 2026
Net transaction value: -$69,905
SEC form: 4
Accepted by SEC: 08 Jul 2026, 20:19:45 UTC
Prior SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt

Key filing fact

Douglas M. Hunt filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 08 Jul 2026.

Key facts

This page summarizes Douglas M. Hunt's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jul 2026, 20:19.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: -$69,905.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727172 Primary reporting owner

HUNT DOUGLAS M

Relationship: The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.
Address: C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES
Signature: /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt
Signature date: 08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBYI transaction

Common Stock

Sale

Transaction value: $69,905
Shares: -8,460
Change %: -4.1%
Price: $8.26
Shares after: 196,841
Date: 06 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

SEC remarks

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.